Rhythm Pharmaceuticals, Inc. (RYTM)
108.79
-1.07
(-0.97%)
USD |
NASDAQ |
Nov 13, 09:56
Rhythm Pharmaceuticals Free Cash Flow (Quarterly) : -3.562M for Sept. 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -3.562M |
| June 30, 2026 | -9.152M |
| March 31, 2026 | -44.18M |
| December 31, 2025 | -26.34M |
| September 30, 2025 | -66.62M |
| June 30, 2025 | -23.31M |
| March 31, 2025 | -40.35M |
| December 31, 2024 | -18.84M |
| September 30, 2024 | -25.72M |
| June 30, 2024 | -29.08M |
| March 31, 2024 | -80.74M |
| December 31, 2023 | -29.38M |
| September 30, 2023 | -29.52M |
| June 30, 2023 | -41.96M |
| March 31, 2023 | -41.00M |
| December 31, 2022 | -34.00M |
| September 30, 2022 | -47.08M |
| June 30, 2022 | -42.87M |
| March 31, 2022 | -53.76M |
| December 31, 2021 | -45.54M |
| September 30, 2021 | -40.27M |
| June 30, 2021 | -32.09M |
| Date | Value |
|---|---|
| March 31, 2021 | -33.54M |
| December 31, 2020 | -29.21M |
| September 30, 2020 | -27.16M |
| June 30, 2020 | -29.73M |
| March 31, 2020 | -36.10M |
| December 31, 2019 | -32.22M |
| September 30, 2019 | -33.86M |
| June 30, 2019 | -27.86M |
| March 31, 2019 | -32.19M |
| December 31, 2018 | -21.38M |
| September 30, 2018 | -17.26M |
| June 30, 2018 | -12.49M |
| March 31, 2018 | -11.65M |
| December 31, 2017 | -7.94M |
| September 30, 2017 | -8.495M |
| June 30, 2017 | -6.142M |
| March 31, 2017 | -7.016M |
| September 30, 2016 | -4.514M |
| June 30, 2016 | -6.635M |
| March 31, 2016 | -6.948M |
| December 31, 2015 | -3.453M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 271.15M |
| BioMarin Pharmaceutical, Inc. | 165.35M |
| Cytokinetics, Inc. | -124.72M |
| Exelixis, Inc. | 277.47M |
| Ionis Pharmaceuticals, Inc. | -193.63M |